Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +38.76%
#2 Purr Purr +34.19%
#3 Siren Siren +30.59%
#4 OriginTrail OriginTrail +18.15%
#5 UnifAI Network UnifAI Network +12.88%
#6 Zora Zora +12.79%
#7 Collect on Fanable Collect on Fanable +11.98%
#8 龙虾 (Lobster) 龙虾 (Lobster) +11.94%
#9 DigiByte DigiByte +11.71%
#10 Ethena Staked ENA Ethena Staked ENA +11.62%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Classifica tra le azioni #21774
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Prezzo delle azioni
$1.11
Ultima sincronizzazione: 2026-08-21
Capitalizzazione di mercato
$100.55M
Variazione (1 giorno)
-7.69%
Variazione (1 anno)
-7.17%
Paese
TW
Scambia Senhwa Biosciences, Inc. (6492)

Categoria

Healthcare
Storico del prezzo dell'azione per Senhwa Biosciences, Inc. (6492)
Prezzo di chiusura più alto: $1.20 il 2026-08-01

Prezzo di chiusura più basso: $3.18 il 2014-12-01
Storico del prezzo dell'azione di Senhwa Biosciences, Inc. dal 2014 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 9.09%
2025 -0.30%
2024 -22.02%
2023 -15.51%
2022 -44.72%
2021 -53.30%
2020 275.09%
2019 -9.86%
2018 3.54%
2017 -60.65%
2016 1.24%
2015 74.07%
2014 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.70 -15.60%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH